Sequoia Capital, founded in 1972 and based in Menlo Park, California, is a prominent venture capital firm that invests in early to growth stage companies across various sectors, including technology, healthcare, financial services, and consumer services. The firm specializes in supporting startups and emerging growth companies, typically investing between $100,000 and $1 million in seed companies, $1 million to $10 million in early ventures, and $10 million to $100 million in growth investments. Sequoia Capital operates globally, with a presence in regions such as Israel, China, and Southeast Asia, and has built a diverse portfolio that includes notable companies like Airbnb, Alibaba, and JD.com. The firm emphasizes a partnership approach with entrepreneurs, leveraging decades of experience to guide them from initial concept through to public offering and beyond.
Full-Life Technologies Limited is a global company specializing in RadioTherapeutics, with its headquarters in Shanghai, China, and operations extending to Europe. The firm focuses on targeted cancer therapy services within the radiotherapy field, aiming to enhance treatment outcomes for cancer patients. Full-Life is dedicated to advancing nuclear medicine through innovative research in radiopharmaceuticals, which supports healthcare providers in delivering effective cancer treatments.
Grit Science
Series A in 2022
Grit Science is a gene therapeutics firm, that engages in the R&D of liver genes.
ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.
Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.
Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.
Bexion is a software-based species design, biomanufacturing and biotechnology ecological company. Aiming at software-engineered species design - giving full play to the self-replication and scalability of biological software and hardware, establishing a modular genome code base, a rapid iteration platform, and completely unlocking the productivity of the biological industry. Beisheng's products are artificial species libraries and related pipelines that meet specific industrial purposes, focusing on the research and development of food, daily chemicals, and protein drugs.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Analytical Biosciences focuses on the development of single-cell genome technologies to enhance the understanding and treatment of human diseases. By collaborating with medical research institutions, hospitals, and pharmaceutical companies, the company leverages single-cell genomics and bioinformatics to create detailed maps of diseases. This approach allows for large-scale systematic disease mapping and the mining of extensive data sets, which aids partners in identifying new therapeutic targets and formulating innovative treatment strategies. Analytical Biosciences employs high-resolution databases and advanced data analytics to facilitate the discovery and validation of novel cellular targets and biomarkers, ultimately contributing to the development of next-generation therapeutics and diagnostics.
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.
Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.
Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.
Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.
Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing and significantly improving survival rates for cancer patients. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in disease-specific treatments designed to target tumors effectively at their roots. As of June 1, 2016, Stemcentrx operates as a subsidiary of AbbVie, further enhancing its capabilities in cancer research and treatment development.
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India.
MedGenome Labs Private Ltd. specializes in molecular genetic diagnostic testing, utilizing advanced technologies such as Sanger sequencing and next-generation sequencing to support personalized healthcare. The company offers a comprehensive range of genetic tests, including exome, whole genome, and mitochondrial genome sequencing, alongside various disease panels. These panels focus on hereditary cancers, somatic mutations in tumors, and genetic conditions affecting cardiac, eye, and neuromuscular health. Additionally, MedGenome provides targeted tests for genetic mutations linked to non-syndromic deafness and autism spectrum disorders. The company also maintains OncoMD, a database of cancer-related mutations sourced from peer-reviewed research. MedGenome's services are designed to guide clinicians in identifying appropriate treatment options based on genetic variations and assessing disease risk. Established in 2013 and headquartered in Chennai, India, MedGenome operates as a subsidiary of SciGenom Labs Pvt Ltd and collaborates strategically with Denali Therapeutics to enhance its research capabilities.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology, particularly in the field of oncology. Based in Foster City, California, the company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, designed for use in metastatic and rare cancers, as well as for patients who have exhausted standard treatment options or are exploring clinical trials. Lifecode aims to facilitate informed treatment decisions by providing clinical information to healthcare providers. To address the complexities of genomic data interpretation, Lifecode has assembled a skilled team with expertise in various scientific disciplines, including data science and molecular biology. The company is supported by funding from prominent investors, and it operates with a dual focus on software development and clinical laboratory services. Lifecode’s innovative approach is positioned to enhance personalized cancer care through accessible and interpretable genomic insights.
Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing and significantly improving survival rates for cancer patients. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in disease-specific treatments designed to target tumors effectively at their roots. As of June 1, 2016, Stemcentrx operates as a subsidiary of AbbVie, further enhancing its capabilities in cancer research and treatment development.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Cellworks Group Inc. is a life sciences technology company that develops a therapeutics platform aimed at predicting effective treatments for patients with oncology and immunology conditions. The company offers The Cellworks, a biosimulation platform that analyzes the genomic profiles of tumors to generate a Therapy Response Index, indicating patient responsiveness to approved therapies. Additionally, Cellworks provides solutions like Cellworks Singula, which helps clinicians determine responses to standard care therapies, and Cellworks Ventura, which suggests targeted therapeutic regimes tailored to individual tumor profiles. The company's technology also encompasses drug and biomarker discovery across various diseases, including inflammatory conditions and neurodegenerative disorders. Founded in 2005, Cellworks is headquartered in South San Francisco, California, with a research and development facility in Bangalore, India, serving a diverse clientele that includes physicians, payers, and biopharma companies.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Lifecode, Inc. is a molecular diagnostics company specializing in next-generation sequencing (NGS) technology, particularly in the field of oncology. Based in Foster City, California, the company develops a range of NGS-based cancer assays, including its flagship product, the Lifecode Pan Cancer Somatic Panel, designed for use in metastatic and rare cancers, as well as for patients who have exhausted standard treatment options or are exploring clinical trials. Lifecode aims to facilitate informed treatment decisions by providing clinical information to healthcare providers. To address the complexities of genomic data interpretation, Lifecode has assembled a skilled team with expertise in various scientific disciplines, including data science and molecular biology. The company is supported by funding from prominent investors, and it operates with a dual focus on software development and clinical laboratory services. Lifecode’s innovative approach is positioned to enhance personalized cancer care through accessible and interpretable genomic insights.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
Natera is a diagnostic and research company specializing in genetic testing services, primarily focused on preconception and prenatal testing. Its flagship product, Panorama, is a non-invasive prenatal test that screens for chromosomal abnormalities in fetuses through a blood draw from the mother, including assessments for twin pregnancies. Other offerings include Vistara, which tests for single-gene disorders, and Horizon carrier screening to identify carrier status for various genetic diseases. Natera also provides the Anora test for analyzing fetal chromosomes in cases of miscarriage and non-invasive paternity testing. Additionally, the company has developed Signatera, a technology that detects circulating tumor DNA to monitor cancer recurrence. Natera utilizes a direct sales force and a network of approximately 100 laboratory and distribution partners for product distribution. The company was founded in 2003, has undergone several name changes, and is headquartered in San Carlos, California. Its collaborations with organizations like BGI Genomics and Foundation Medicine further enhance its capabilities in genetic testing and personalized medicine.
GVK Biosciences Private Limited is a prominent contract research and development organization based in Hyderabad, India, with additional offices in the United States and the Netherlands. Founded in 2000, the company specializes in providing a comprehensive range of drug discovery and development services to the biopharma, biotechnology, agrochemical, and academic sectors. GVK Biosciences offers integrated drug discovery, chemistry and biology services, large molecule research and development, as well as chemical development, formulation, analytical development, and contract manufacturing. With a workforce of approximately 2,400 employees, the company focuses on delivering high-quality results with speed and efficiency, serving over 300 clients worldwide, including leading pharmaceutical and biotechnology firms. GVK Biosciences has established a reputation for excellence in the industry, consistently meeting and exceeding customer expectations in drug discovery and development.
Sai Life Sciences Ltd. specializes in the discovery, contract development, and manufacturing of pharmaceuticals for clients in the biotechnology and pharmaceutical sectors. The company offers a comprehensive range of services, including discovery solutions such as synthetic and medicinal chemistry, toxicology, and pharmacology, as well as development services like analytical method validation, stability studies, and formulation development. Additionally, Sai Life Sciences provides manufacturing capabilities for late-phase and commercial products, along with technology transfer services. With a presence in key markets including India, the United States, the European Union, and Japan, the company has established research and manufacturing facilities in Hyderabad, Pune, Bidar, Cambridge, and Manchester. Founded in 1999 and formerly known as SAI Advantium Pharma Limited, Sai Life Sciences is focused on helping its clients accelerate the development of innovative medicines while minimizing risks and costs.
BioSpace, Inc. operates an online platform that serves as a community for life science professionals, offering industry news and career opportunities. Through its website, BioSpace.com, the company provides a job board alongside daily feeds of biotechnology news and features that facilitate connections among recruiters, job seekers, and industry experts. By fostering communication and collaboration among business and scientific leaders, BioSpace enhances recruitment and professional development within the biotechnology, pharmaceuticals, medical devices, diagnostics, clinical research, academic, and biomedical sectors. Additionally, the company organizes career events aimed at life science recruiting professionals across the United States and Canada. Headquartered in Englewood, Colorado, with an office in San Francisco, California, BioSpace is recognized as a key resource for industry news and career advancement.
Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Develops a line of diagnostic and therapeutic products for diabetics. Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside the box". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.
Vical's core technology grew out of a chance discovery and provided the cornerstones for two new biopharmaceutical industry sectors: DNA vaccines and non-viral gene therapy.
Vical's management systematically leveraged that technology into a broad portfolio of independent and partnered product development programs. The first products for animal health are on the market. The first human products are approaching.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.